

USP19 Antibody (internal region)
Peptide-affinity purified goat antibody
Catalog # AF2786a**Specification**

USP19 Antibody (internal region) - Product Information

Application	E
Primary Accession	O94966
Other Accession	NP_006668.1 , 10869
Predicted	Human
Host	Goat
Clonality	Polyclonal
Concentration	0.5 mg/ml
Isotype	IgG
Calculated MW	145651

USP19 Antibody (internal region) - Additional Information**Gene ID** 10869**Other Names**

Ubiquitin carboxyl-terminal hydrolase 19, 3.4.19.12, Deubiquitinating enzyme 19, Ubiquitin thioesterase 19, Ubiquitin-specific-processing protease 19, Zinc finger MYND domain-containing protein 9, USP19, KIAA0891, ZMYND9

Dilution

E~~N/A

Format

0.5 mg/ml in Tris saline, 0.02% sodium azide, pH7.3 with 0.5% bovine serum albumin

Storage

Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.

Precautions

USP19 Antibody (internal region) is for research use only and not for use in diagnostic or therapeutic procedures.

USP19 Antibody (internal region) - Protein Information**Name** USP19**Synonyms** KIAA0891, ZMYND9**Function**

Deubiquitinating enzyme that regulates the degradation of various proteins by removing ubiquitin

moieties, thereby preventing their proteasomal degradation. Stabilizes RNF123, which promotes CDKN1B degradation and contributes to cell proliferation (By similarity). Decreases the levels of ubiquitinated proteins during skeletal muscle formation and acts to repress myogenesis. Modulates transcription of major myofibrillar proteins. Also involved in turnover of endoplasmic-reticulum-associated degradation (ERAD) substrates (PubMed:19465887, PubMed:24356957). Mechanistically, deubiquitinates and thereby stabilizes several E3 ligases involved in the ERAD pathway including SYVN1 or MARCHF6 (PubMed:24356957). Regulates the stability of other E3 ligases including BIRC2/c-IAP1 and BIRC3/c-IAP2 by preventing their ubiquitination (PubMed:21849505). Required for cells to mount an appropriate response to hypoxia by rescuing HIF1A from degradation in a non-catalytic manner and by mediating the deubiquitination of FUNDC1 (PubMed:22128162, PubMed:33978709). Attenuates mitochondrial damage and ferroptosis by targeting and stabilizing NADPH oxidase 4/NOX4 (PubMed:38943386). Negatively regulates TNF-alpha- and IL-1beta- triggered NF-kappa-B activation by hydrolyzing 'Lys-27'- and 'Lys-63'- linked polyubiquitin chains from MAP3K7 (PubMed:31127032). Modulates also the protein level and aggregation of polyQ-expanded huntingtin/HTT through HSP90AA1 (PubMed:33094816).

Cellular Location

Endoplasmic reticulum membrane; Single-pass membrane protein. Note=Accumulates in the mitochondria-associated ER membrane (MAM) in response to hypoxia

USP19 Antibody (internal region) - Protocols

Provided below are standard protocols that you may find useful for product applications.

- [Western Blot](#)
- [Blocking Peptides](#)
- [Dot Blot](#)
- [Immunohistochemistry](#)
- [Immunofluorescence](#)
- [Immunoprecipitation](#)
- [Flow Cytometry](#)
- [Cell Culture](#)

USP19 Antibody (internal region) - Images

USP19 Antibody (internal region) - References

High incidence of ubiquitin-like domains in human ubiquitin-specific proteases. Zhu X, Ménard R, Sulea T. Proteins. 2007 Oct 1;69(1):1-7 PMID: 17597129